公司资料
X4 Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- XFOR
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
4.30 USD (+1.90%)
收盘价
最后更新: 2026年8月17日
381M USD
市值
股价为何变动
As of Aug 17, 2026, XFOR closed up 1.90% at $4.30. No new same-company headline was identified in the current news window.
公司概览
Rare Hematology Focus
X4 Pharmaceuticals develops therapies for rare disorders in which dysregulated CXCR4 signaling contributes to abnormal retention of immune cells in bone marrow. Its lead molecule, mavorixafor, is an oral CXCR4 antagonist designed to mobilize neutrophils into circulation.
Chronic Neutropenia Development
Mavorixafor is being evaluated in the global pivotal 4WARD Phase 3 trial for congenital, acquired primary autoimmune and idiopathic chronic neutropenia. The study tests once-daily mavorixafor, with or without G-CSF, in patients who experience recurrent or serious infections.
Approved WHIM Syndrome Product
Mavorixafor is approved as XOLREMDI for WHIM syndrome, including authorization in the European Union. X4 has partnered with Norgine for European commercialization, giving the company a partner-led route to expand access while concentrating internal resources on clinical development.
未来催化剂
- Completion of enrollment in the 4WARD Phase 3 chronic neutropenia trial expected by the end of the third quarter of 2026.
- Transfer of the European XOLREMDI marketing authorization to Norgine planned later in 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。